Protease Inhibitors: General Research
- Protease Inhibitors and Atherosclerosis (January/February 2003)
In TAGline, from Treatment Action Group
- Research From the 42nd ICAAC: Two PIs vs. Two PIs vs. Efavirenz (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
On TheBodyPRO.com
- Immune Reconstitution Is Similar in Antiretroviral-Naive Subjects Following 1 Year of Therapy With a Triple NRTI-Based or Protease Inhibitor-Containing ARV Regimen (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
- 104 Weeks Outcome of Simplified Regimens in PI-Experienced Patients (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
- Study Finds Protease Inhibitors May Help Cause Lipodystrophy (October 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
On TheBodyPRO.com
- Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Study Examines Mortality Factors in HIV Patients on Protease Inhibitors (October 10, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
On TheBodyPRO.com
- Data From the 14th International AIDS Conference: Spare the PIs (October 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
On TheBodyPRO.com
- Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Perspective of HIV-Associated Coronary Heart Disease (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Saquinavir With Low-Dose Ritonavir Twice Daily (May 9, 2002)
From Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens (April 15, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
On TheBodyPRO.com
- A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV (March 11, 2002)
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project
On TheBodyPRO.com
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV) (December 19, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
